| Pfizer's COVID-19 vaccine has been found to be 100% effective in young adolescents, according to an announcement from the company.
On Wednesday, the company released findings from its trial including participants aged 12 to 15 years, saying the vaccine demonstrated 100% real efficacy for those with and without prior evidence of COVID-19 infection.
"We share the urgency to expand the use of our vaccine to additional populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15," said Albert Bourla, chairman and chief executive officer of Pfizer.
Pfizer plans to submit the data to the U.S. Food and Drug Administration in the coming weeks for a requested amendment to the vaccine's emergency use authorization, with the hope of starting to vaccinate the age group before the start of the next school year.
The trial enrolled 2,260 adolescents 12 to 15 years of age. Because it's a small study that hasn't yet been published, another important piece of evidence will be how well the participants' immune systems responded. Researchers reported high levels of virus-fighting antibodies, somewhat higher than were seen in studies of young adults.
Kids had side effects similar to young adults, the company said. The main side effects are pain, fever, chills and fatigue, particularly after the second dose. The study will continue to track participants for two years for more information about long-term protection and safety.
All participants in the trial will continue to be monitored for long-term protection and safety for an additional two years after their second dose. | 
No comments:
Post a Comment
Keep a civil tongue.